(b)(4).There was no reported device malfunction and the product was not returned.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.The reported patient effects of intracranial hemorrhage and neurological deficit/dysfunction, as listed in the xact instructions for use, are known adverse events associated with the use of a carotid device in native carotid arteries.Based on the case information and related record review, a conclusive cause for the reported patient effects and the relationship to the product, if any, cannot be determined and there is no indication of a product quality issue with respect to design, manufacture or labeling of the device.
|
It was reported that the procedure, on (b)(6) 2017, was to treat the right internal carotid artery.The emboshield nav6 was placed followed by successful implantation of the 9-7x40 xact stent.After the xact stent was implanted, there was no flow distal to the stent and the patient was noted to have slurred speech.Medication (tpa) was administered to break up any potential clot and an aspiration catheter was used to remove debris from the emboshield nav6.The filter was then removed and distal flow was restored.The slurred speech improved, but was still present.Visual examination of the filter identified the debris that was in the filter appeared to be calcium rather than clot.The procedure was completed and the patient was sent for a ct scan.An intracranial bleed was noted.On an unknown date, the patient was unable to speak and was in a vegetative state.No additional information was provided.
|